MIRISK and MIRISK VP are a new set of genetic blood tests that can help identify the major causes of transmitted diseases that affect the heart and vasculature (the system that delivers blood to the entire body). The MIRISK and MIRISK VP assessments identify individuals who are at risk of a cardiac event within the next five years.
This type of testing can be the difference between effective disease management and needless risk of sudden cardiac death.
Genetic testing can help determine a successful course of treatment for the patient, as well as identify any familial testing needs generated from a positive result. In many instances the first indication that an individual is affected is sudden cardiac death; hence testing is key to preventing a catastrophic event. This information can lead a patient to make successful lifestyle changes and pursue therapy to live a healthy and successful life, despite the disease.
Dr. Doug Harrington, MD, has over 25 years of experience in the commercialization of healthcare technology and is the CEO of Aviir, a biotechnology company dedicated to the prevention of cardiovascular disease through innovative laboratory tests.